Through the years, Hosune has built an impressive record as an effective antibiotic in common bacterial respiratory infections. Numerous published clinical studies attest to excellent therapeutic response with Ilosone. Decisive recovery has become a matter of record.

Litty

The mual donage for infants aml for children under twenty-five poorida is 5 mg, per pound every six bours, for chahiren up to fifty pounds, 127 mg every six buts.

For adults and for ebakeren isver filty posils, the wual dosage in 250 mg every sits hours.

In more severe or deep-seated infections, flew idosages may he shouldest.

Bosne is available is there convenient forms. Polvules® 125 and 20 mg. 1: Oral Suspension -- 123 mg † per sec, tempomofuli ami Unipa ~5 isig,† per drop, with dropper cahtrated at 25 and 50 mg. Product brochure available, wede Eli Lilly and Company, Ledianapolis 6. Indiana.

EXHIBIT 8

INSULIN LICENSE AGREEMENT BETWEEN THE GOVERNORS OF THE UNIVERSITY OF TORONTO AND ELI LILLY & Co.

AGREEMENT made the 23rd day of December, 1953, between :

The Governors of the University of Toronto, hereinafter called "the University" of the first part, and Eli Lilly and Company, a corporation of the state of Indiana, of Indianapolis, Indiana, hereinafter called "the Licensee" of the second part,

Whereas the University owns in some instances and in other instances has rights under a number of patents relating to Insulin preparations, or methods of preparing the same,

And whereas the said patents include the letters patent of the United States of America listed in Schedule "A" hereto and owned by the University and the letters patent of the United States of America listed in Schedule "B" hereto under which the University has licensing rights:

And whereas it is and always has been the desire of the University to grant licenses:

And whereas the Licensee has rights, privileges and responsibilities under one or more licenses previously granted by the University with respect to the letters patent of invention hereinafter referred to, which rights, privileges and responsi bilities it is desired to continue in effect but to modify and clarify in some respects:

Now this Agreement witnesseth that in consideration of the premises it is hereby agreed by and between the parties hereto as follows:

1. (a) Wherever used in this agreement, unless there is something in the context inconsistent therewith, "Committee" means the Insulin Committee of the University; "substance" means and includes any material which embodies any of the inventions of any present or future patent licensed under this agreement and which at the time is unexpired and has not been declared by a competent court of last resort to be invalid, and any material which is prepared or produced by any process or method embodying any of the inventions of any such patent; "product" means any material which is not a substance but which utilizes a substance in its manufacture; "improvement" means and includes any invention, discovery or development the manufacture or use of which by any one other than the holder of or licensee under the present and future patents licensed under this agreement and which at the time are unexpired and have not been declared by a competent court of last resort to be invalid would constitute infringement of one or more of the claims thereof.

(b) Reference herein to any schedule means and includes the schedule as originally written and attached to this agreement and any revision thereof or amendment thereto from time to time made in accordance with this agreement. (c) All rights and privileges conferred upon the University by the terms of this agreement may be exercised and enforced by the Committee and any act. notice or specification on behalf of the University shall be sufficient if done. given or issued by the Committee.

2. Subject to the provisions, conditions and limitations hereinafter contained the University grants to the Licensee the non-exclusive right, license and privilege:

(a) of making, using and selling the inventions of the letters patent of the United States of America listed in Schedules "A" and "B" during the continuance of the said patents and any extensions or renewals thereof; and

(b) of making, using and selling during the continuance of the patent or patents therefor and any extensions and renewals thereof the inventions of any and all letters patent of the United States of America for improvements which during the currency of this agreement shall be granted or assigned to or become vested in the University.

3. Nothing in this agreement shall be construed as proposing, implying or granting a licence under any patent or patent application in any country other than the United States of America, whether such foreign patent or application be owned by the University or by others.

4. If during the currency of this agreement the University shall acquire and hold a licence (with power to sub-license) to make, use and sell the invention of any letters patent of the United States of America not owned by it for an improvement it will, subject to the limitations and restrictions of its licence, make available to the Licensee by way of sub-licence the right, licence and privilege of making, using and selling the invention of such letters patent upon the payment of such royalty as may be considered by the University to be appropriate having regard to the royalty payable by it and otherwise upon terms, conditions and limitations similar to those contained in this agreement, save as they may be required to be amended or revised to be made consistent with the licence to the University.

5. The obligations of the Licensee in respect of any substance shall, if this licence has not been previously terminated, cease upon the expiration of the last to expire of the letters patent of the United States of America referred to in paragraph 2 under which such substance is made or sold. At the request of the Licensee this agreement may be continued as to any of the letters patent of the United States of America referred to in paragraph 2 beyond its normal expiry date for such period as may be agreed by the parties and also at the request of the Licensee this agreement may be extended to apply to any letters patent of the United States of America relating to insulin not made from insulin crystals expired at the date of this agreement for such period as may be agreed by the parties.

6. In order that maximum public advantage may continue to accrue from operations under the licence hereby granted:

(a) The University shall from time to time promptly and without delay communicate to the Licensee for its own use only any and all improvements (whether patentable or not) which during the term of this agreement may be made or discovered by the University or on its behalf and shall fully disclose to the Licensee the manner of performing the same:

(b) The Licensee shall from time to time promptly and without delay communicate to the University any and all improvements (whether patentable or not) which during the term of this agreement may be made or discovered by the Licensee or on its behalf and shall fully disclose to the University the manner of performing the same and shall grant to the University the non-exclusive right, licence and privilege (including the right to grant sub-licences) of making, using and selling the inventions comprised in any and all letters patent of the United States of America and of Canada relating to such improvements. Such non-exclusive right, licence and privilege shall be royalty free or insofar as the United States of America is concerned may require the payment of royalty at rates not exceeding fifty per cent (50%) of those permitted under this agreement.

7. In the case of any substance, the University may require that Licensee shall not commence distribution of the substance until a duly-accredited representative of the University has inspected the facilities and records being used and kept by Licensee in manufacturing and testing the substance, and has notified Licensee in writing that the said facilities and records are considered adequate.

8. Any substance distributed, sold or utilized in the manufacture of a product by the Licensee shall conform to and satisfy the standards of identity, strength, quality and purity for the substance as

(i) are then currently applicable under The Pharmacopeia of the United States of America or the Federal Food, Drug and Cosmetic Act of the U.S.A. or Regulations under said Act, or by action of any office or agency of the Government of the United States of America, and

(ii) are currently established from time to time by the University and are not inconsistent with the foregoing:

and the License shall not make, distribute, sell or utilize any substance unless and until standards of identity, strength, quality and purity applicable thereto have been established by or under the authorities referred to in subparagraph (i) above or by specifications of the University. Schedule "C" sets forth the substances for which specifications have been issued by the University and the fields to which such specifications apply.

9. The Licensee shall from time to time (unless and until the University shall in writing otherwise direct) promptly submit to the University :

(i) trial dilutions or trial mixtures of each lot of any substance before any batch from such lot is distributed, sold or utilized by the Licensee and none of any lot shall be distributed, sold or utilized by the Licensee until the University has notified the Licensee that it is satisfied with the trial dilution or trial mixture thereof submitted and until all the University's requirements as prescribed in this Agreement are met:

(ii) samples of each batch of any substance being distributed, sold or utilized by the Licensee, such samples to be selected at random from the Licensee's stocks of the batch as and when the same has been put into stock for distribution, sale or utilization by the Licensee.

10. If and whenever the Licensee shall in the manufacture, distribution or utilization of any substance fail to use safe and adequate methods or processes or fail to maintain standards required by good scientific practice in that behalf or shall distribute, offer for sale, sell or utilize any substance which fails to comply with the standards referred to in paragraph 8 hereof, the University by sixty days' prior written notice may suspend all rights and privileges hereby conferred upon the Licensee and all other licences granted to the Licensee until the requirements of the University as to such methods, processes and standards are complied with by the Licensee to the reasonable satisfaction of the University. If the Licensee after receiving any such notice shall for six months fail to comply with the said requirements to the reasonable satisfaction of the University, the University shall (notwithstanding any waiver by the University of, or any failure by it to take advantage of, any prior failures or defaults) have the right forthwith to terminate the licence hereby granted and all other licences granted to the Licensee.

11. The University shall notify the Licensee in writing of the proper name to be applied to each substance by the Licensee and other licensees of the University and the Licensee shall use such name for such substance (or such appropriate translation thereof as may be approved by the University for purposes of export from the United States of America) and without the consent in writing of the University shall not use any other word, trade mark, trade or other name as an alternative or substitute therefor. The Licensee may apply "Insulin" to all products containing insulin made or sold under this licence and shall do so unless the University permits otherwise by written authorization, and may continue to do so after the expiration of this licence.

12. The License shall have the right, in order to identify a substance to be of Licensee's manufacture,

(i) to use Licensee's name or a customary abbreviation thereof or a word thereof or a word of the name of the Licensee's biological, drug or pharmaceutical laboratories or division in conjunction with the name referred to in paragraph II hereof, and

(ii) to use, subject to the provisions of paragraph 11, the symbols, designs or trade marks customarily used by the Licensee in the labelling. advertising or sale of its products.

13. No advertising material or literature (including, without limiting the generality of the foregoing, labelling as defined and interpreted in the U.S. Federal Food, Drug and Cosmetic Act and regulations thereunder) regarding any substance or referring to the University shall be used or distributed by the Licensee until the same has been approved in writing by the University. Following the approval of any such material or literature in the English language, the Licensee may use and distribute the same material and literature translated into any other language.

14. The Licensee shall at all times sell any substance at moderate, fair and reasonable prices. If the University believes that the selling prices of the Licensee are excessive and the parties hereto cannot come to a satisfactory agreement regarding a readjustment of same, the question as to whether the selling prices of the Licensee are excessive and if so what would be moderate. fair and reasonable prices shall be submitted to a board of arbitration composed of three persons, one appointed by each of the parties hereto and the third selected by the two so appointed, and the finding of a majority of such arbitrators shall be final and the Licensee shall have the right and privilege